Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) EBITDA (2016 - 2025)

Cardiff Oncology's EBITDA history spans 15 years, with the latest figure at -$7.8 million for Q4 2025.

  • For Q4 2025, EBITDA rose 37.74% year-over-year to -$7.8 million; the TTM value through Dec 2025 reached -$49.0 million, down 0.64%, while the annual FY2025 figure was -$49.0 million, 0.64% down from the prior year.
  • EBITDA for Q4 2025 was -$7.8 million at Cardiff Oncology, up from -$12.0 million in the prior quarter.
  • Across five years, EBITDA topped out at -$5.4 million in Q1 2021 and bottomed at -$14.8 million in Q2 2025.
  • The 5-year median for EBITDA is -$10.9 million (2023), against an average of -$10.6 million.
  • The largest annual shift saw EBITDA tumbled 103.49% in 2022 before it soared 37.74% in 2025.
  • A 5-year view of EBITDA shows it stood at -$9.5 million in 2021, then grew by 1.41% to -$9.4 million in 2022, then decreased by 10.01% to -$10.3 million in 2023, then dropped by 21.68% to -$12.6 million in 2024, then skyrocketed by 37.74% to -$7.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's EBITDA are -$7.8 million (Q4 2025), -$12.0 million (Q3 2025), and -$14.8 million (Q2 2025).